Human ccRCC 786-O (Williams et al., 1978 (
link)) and ACHN (Kochevar, 1990 (
link)) cell lines (American Type Culture Collection, ATCC, Manassas, VA, USA) were grown in
RPMI 1640 medium and
Dulbecco’s modified Eagle’s medium (DMEM) (both from Gibco, Waltham, MA, USA), respectively. These media contain 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) and 1%
antibiotic-antimycotic agent (Life Technologies, Inc., Grand Island, NY, USA). Cells were grown at 37 °C and 5% CO
2.
Small interfering RNA (siRNA) duplexes pools directed against ELK1 (sc-35290) and control scrambled RNAi (
sc-37007) were bought from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were grown to 80% confluency in 35-mm dishes, transfected with 2 µl
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), and mixed with 30 pmol of the synthetic ELK1 siRNA pool. The cells were then harvested and analyzed after 48 h of transfection.
The primary antibodies specific for ELK1 was bought from Santa Cruz,
NDUFA4L2 and
GAPDH antibodies were purchased from Abcam (Cambridge, MA, USA).
Wang L., Peng Z., Wang K., Qi Y., Yang Y., Zhang Y., An X., Luo S, & Zheng J. (2017). NDUFA4L2 is associated with clear cell renal cell carcinoma malignancy and is regulated by ELK1. PeerJ, 5, e4065.